• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Therapy with the Combination of Tolvaptan and Furosemide for Refractory Edema in Nephrotic Syndrome.

作者信息

Meena Jitendra, Sinha Aditi, Hari Pankaj, Bagga Arvind

机构信息

Division of Nephrology, Department of Pediatrics, ICMR Center for Advanced Research in Nephrology, All India Institute of Medical Sciences, New Delhi, India.

出版信息

Indian J Nephrol. 2020 Jan-Feb;30(1):53-55. doi: 10.4103/ijn.IJN_358_18. Epub 2019 Sep 6.

DOI:10.4103/ijn.IJN_358_18
PMID:32015605
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6977386/
Abstract
摘要

相似文献

1
Therapy with the Combination of Tolvaptan and Furosemide for Refractory Edema in Nephrotic Syndrome.托伐普坦与呋塞米联合治疗肾病综合征难治性水肿
Indian J Nephrol. 2020 Jan-Feb;30(1):53-55. doi: 10.4103/ijn.IJN_358_18. Epub 2019 Sep 6.
2
Acetazolamide and Hydrochlorothiazide Followed by Furosemide Versus Furosemide and Hydrochlorothiazide Followed by Furosemide for the Treatment of Adults With Nephrotic Edema: A Randomized Trial.乙酰唑胺和氢氯噻嗪序贯呋塞米与呋塞米和氢氯噻嗪序贯呋塞米治疗肾病性水肿成人患者的随机试验。
Am J Kidney Dis. 2017 Mar;69(3):420-427. doi: 10.1053/j.ajkd.2016.10.022. Epub 2016 Dec 30.
3
Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide.托伐普坦可缓解对呋塞米无反应的肾病性糖尿病肾衰竭患者的过多液体潴留。
Nephrology (Carlton). 2018 Sep;23(9):883-886. doi: 10.1111/nep.13390.
4
Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model.托伐普坦单药治疗及低剂量呋塞米/托伐普坦联合治疗对大鼠肝硬化模型肝保护和利尿作用的有效性
J Clin Biochem Nutr. 2017 Jul;61(1):53-59. doi: 10.3164/jcbn.16-122. Epub 2017 May 16.
5
Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease.托伐普坦和呋塞米对一名肝硬化合并慢性肾脏病患者液体分布的不同影响
Intern Med. 2019 Jun 1;58(11):1587-1591. doi: 10.2169/internalmedicine.2174-18. Epub 2019 Feb 1.
6
Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis.肝硬化患者中呋塞米/托伐普坦联合治疗时呋塞米剂量的变化。
Dig Dis. 2020;38(1):38-45. doi: 10.1159/000501267. Epub 2019 Jun 19.
7
Combined furosemide and human albumin treatment for diuretic-resistant edema.速尿与人体白蛋白联合治疗利尿剂抵抗性水肿。
Ann Pharmacother. 2003 May;37(5):695-700. doi: 10.1345/aph.1C320.
8
Is tolvaptan indicated for refractory oedema in nephrotic syndrome?托伐普坦是否适用于肾病综合征的难治性水肿？
Nephrology (Carlton). 2015 Feb;20(2):103-6. doi: 10.1111/nep.12348.
9
Does albumin and furosemide therapy affect plasma volume in nephrotic children?白蛋白和呋塞米治疗对肾病患儿的血浆容量有影响吗？
Pediatr Nephrol. 2001 Jun;16(6):497-9. doi: 10.1007/s004670100576.
10
Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.在一名难治性腹水患者中，呋塞米剂量减少后对托伐普坦的再次反应。
Clin J Gastroenterol. 2015 Feb;8(1):47-51. doi: 10.1007/s12328-014-0545-8. Epub 2014 Dec 5.

引用本文的文献

1
Endocrine Disorders in Nephrotic Syndrome-A Comprehensive Review.肾病综合征中的内分泌紊乱——全面综述
Biomedicines. 2024 Aug 15;12(8):1860. doi: 10.3390/biomedicines12081860.
2
Nephrotic Syndrome: From Pathophysiology to Novel Therapeutic Approaches.肾病综合征：从病理生理学到新型治疗方法
Biomedicines. 2024 Mar 3;12(3):569. doi: 10.3390/biomedicines12030569.
3
Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome.口服托伐普坦治疗难治性肾病综合征伴重度水肿和低钠血症的疗效。
CEN Case Rep. 2021 Nov;10(4):523-526. doi: 10.1007/s13730-021-00601-1. Epub 2021 Apr 26.

本文引用的文献

1
Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide.托伐普坦可缓解对呋塞米无反应的肾病性糖尿病肾衰竭患者的过多液体潴留。
Nephrology (Carlton). 2018 Sep;23(9):883-886. doi: 10.1111/nep.13390.
2
The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials.血管加压素V2受体拮抗剂治疗肝硬化腹水患者：一项随机对照试验的荟萃分析。
BMC Gastroenterol. 2015 Jun 9;15:65. doi: 10.1186/s12876-015-0297-z.
3
Tolvaptan therapy for massive edema in a patient with nephrotic syndrome.托伐普坦治疗肾病综合征患者的重度水肿
Pediatr Nephrol. 2014 May;29(5):915-7. doi: 10.1007/s00467-013-2687-1. Epub 2013 Nov 19.
4
Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.非肽类血管加压素拮抗剂托伐普坦与呋塞米或氢氯噻嗪之间的药代动力学和药效学相互作用。
J Cardiovasc Pharmacol. 2007 Aug;50(2):213-22. doi: 10.1097/FJC.0b013e318074f934.